Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

While the incidence rate of neuroendocrine tumours has been increasing, the survival rate has not. Therefore, there is a great need for state-of-the-art research and new treatment protocols. The chapters in this book contribute to that debate and will be required reading for both researchers and healthcare practitioners, as it offers both overviews of the condition and specialized contributions. Topics covered include the association between chronic inflammation and gastroenteropancreatic neuroendocrine tumours, or GEP-NETs. GEP-NETs are also addressed in a chapter on their circulating markers, which can help in diagnosing this hard to detect condition. One chapter covers the role of Chromogranin A, while another addresses the diagnosis and management of neuroendocrine carcinomas in cases where the primary site is unknown.

Neuroendocrine tumors. --- Tumors --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This atlas provides descriptive information on the cytopathology of neuroendocrine tumor types and differential diagnoses. It addresses the wide distribution of the neuroendocrine cells in the body and provides detailed descriptions of the morphologic spectrum of the neoplasms (including different terminologies), and their immunocytohistochemical properties, associated ultrastructural findings, secretory products, and their association with many hereditary syndromes.

Endocrine glands --- Tumors. --- Cytodiagnosis --- Neuroendocrine tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Gastroenteropancreatic neuroendocrine tumors are considered rare diseases according to the Surveillance Epidemiology. However their incidences are subject to a constant increase. On the other hand, the medical profession possesses a medicinal arsenal to counter such illness gradually more specific and Jess harmful treatments penetrated the market. Among these treatments, metabolic radiotherapy will be analyzed through this essay. From non- selective approaches such as chemotherapy and surgery to selective approaches such as somatostatine analogues, we will determine the appropriate place of metabolic radiotherapy between these therapies. Les tumeurs Neuroendocrines gastro-entéro-pancréatiques sont considérées comme maladie rare par The US Surveillance Epidemiology. Cependant, leur incidence est en constante augmentation. Peu à peu, des traitements plus spécifiques et moins nocifs sont apparus sur le marché. Parmi ces traitements, nous allons analyser la radiothérapie métabolique. Effectivement, par son mécanisme d'action novateur, elle permet une approche ciblée et efficace. Cependant, le corps médical dispose de tout un arsenal thérapeutique. Passant par des approches non sélectives comme la chimiothérapie et la chirurgie à des approches sélectives comme les simples analogues à la somatostatine, nous allons déterminer quelle est la place de la radiothérapie métabolique parmi ces thérapies.

Radiotherapy --- Neuroendocrine Tumors --- Pancreatic Neoplasms --- Stomach Neoplasms

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Surgery continues to be the mainstay treatment for melanoma localized to the primary tumor and/or lymph nodes. Results from randomized controlled trials indicate that sentinel node biopsy for the treatment of cutaneous melanoma of intermediate thickness has a beneficial effect on recurrence rates, and adjuvant radiotherapy to regional lymph node fields following surgical resection reduces loco-regional recurrence in patients at high risk of relapse. Isolated limb perfusion, electrochemotherapy, and photodynamic therapy continue to be evaluated for treatment of stage IV disease. However, the greatest excitement in new treatment has been with targeted therapies for genetic mutations. In particular, the promising results of partial and complete tumor response in stage IV disease from early phase trials of the B-RAF kinase inhibitors. This book provides a contemporary insight into the therapeutic treatment options for patients with metastatic melanoma and is relevant to clinicians and researchers worldwide. In addition, an update on current clinical trials for melanoma treatment has been included, and two chapters have been reserved to discuss the treatment of oral and uveal melanoma.

Melanoma --- Treatment. --- Malignant melanoma --- Melanocytic tumor --- Cancer --- Neuroendocrine tumors --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Management of melanoma is challenging, especially for the late stage of the disease. Development of new therapies and optimizing current treatments are being pursued in attempt to further improve the survival rate. The book provides up-to-date knowledge and experience in early diagnosis, prevention and treatment of melanoma as well as current ongoing clinical studies on melanoma. The book also provides the most recent perspectives of research on the molecular basis of melanoma, such as melanoma associated genes and a possible link between stress and melanoma.

Melanoma. --- Malignant melanoma --- Melanocytic tumor --- Cancer --- Neuroendocrine tumors --- Oncology